In CD133-positive colon CSCs, knockdown of c-Myc expression upregulates the sensitivity to the anti-cancer drug treatment through the decrease in expression of ATP-binding cassette and multidrug resistance proteins, including ABCG2 and ABCB5 [108], implying that c-Myc might contribute to maintaining the chemoresistance of colon CSCs. This evidence concerns the gene MYC and cancer.